Autologous Stromal Vascular Fraction of Cells for Treatment of Knee Articular Cartilage Dystrophy
Evaluation of Safety and Effectiveness of Intraarticular Administration of Autologous Stromal Vascular Fraction of Cells for Treatment of Knee Articular Cartilage Dystrophy
Sponsor: Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
This PHASE2 trial investigates Knee Osteoarthritis and is currently ongoing. Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Enrolling By Invitation → Unknown Status
▶ Show 4 earlier versions
-
Jun 2018 — Aug 2019 [monthly]
Enrolling By Invitation PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE2
-
Aug 2017 — Oct 2017 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Enrolling By Invitation PHASE2
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
- Orenburg Regional Clinical Blood Donor Center
For direct contact, visit the study record on ClinicalTrials.gov .